【摘要】 目的 为了解Thymosin-α1(T-α1)对活动型乙肝后肝硬变的治疗效果。方法 对20例乙肝后肝硬变活动型患者T-α1的治疗进行了6个月观察分析。结果 HBV-DNA阴转率为47%(8/17)，HBeAg阴转率为43.8%(7/16)。18例患者ALT在治疗中或治疗结束后达到正常，其他并发症有不同程度的改善，无明显不良反应发现。结论 本资料初步提示:T-α1可安全和有效地应用于活动型乙肝后肝硬变。

    Fan Xiaoling，Xui Daozhen

    Beijing Ditan Hospital，Beijing100011.

    【Abstract】 Objective To observe the safety and efficacy of thymosin-α1(T-α1)in the treatment of paˉtients with HBV-induced active liver cirrhosis.Methods Twenty male patients have been diagnosed as liver cirrhoˉsis for2to20years.16patients presented HBeAg positive and17patients HBV-DNA positive.All patients were treated with T-α1for24weeks at the dosage of1.6mg，S.C.，Q.D.for the first two weeks ......